Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

101. Influenza infection modulates vesicular trafficking and induces Golgi complex disruption

Influenza infection modulates vesicular trafficking and induces Golgi complex disruption 28004015 2018 11 13 2347-3584 27 4 2016 Dec Virusdisease Virusdisease Influenza infection modulates vesicular trafficking and induces Golgi complex disruption. 357-368 10.1007/s13337-016-0347-3 Influenza A virus (IFV) replicates its genome in the nucleus of infected cells and uses the cellular protein transport system for genome trafficking from the nucleus to the plasma membrane. However, many details (...) out complementary studies to determine the effect of IFV on intracellular membranes. Inhibition of the CRM1 and TAP-P15 nuclear transport pathways by DRB and LB blocked completely the export of virus. Inhibition of vesicular trafficking by BFA, NOC, and ZWEHD also affected influenza infection. Interestingly, IFV infection induced fragmentation of the Golgi complex resulting in diffuse distribution of large and small vesicles throughout the cytoplasm. Live-cell microscopy revealed expansion

Virusdisease2016 Full Text: Link to full Text with Trip Pro

102. Acute posterior multifocal placoid pigment epitheliopathy and granulomatous uveitis following influenza vaccination

Acute posterior multifocal placoid pigment epitheliopathy and granulomatous uveitis following influenza vaccination 29503928 2018 11 14 2451-9936 4 2016 Dec American journal of ophthalmology case reports Am J Ophthalmol Case Rep Acute posterior multifocal placoid pigment epitheliopathy and granulomatous uveitis following influenza vaccination. 60-63 10.1016/j.ajoc.2016.08.008 To report a case of acute placoid multifocal posterior pigment epitheliopathy (APMPPE) following influenza vaccination (...) . The patient exhibited granulomatous uveitis during the recovery phase. A woman in her thirties developed flu-like symptoms seven days after receiving an influenza vaccination. Approximately 2 weeks later, the patient reported with conjunctival injection, blurred vision, and pain in her left eye. She was examined in our clinic, and the best-corrected visual acuity was 20/15 OD and 20/20 OS. Multiple whitish spots were observed bilaterally in the deep retinal layer along with edema of the left optic disc

American journal of ophthalmology case reports2016 Full Text: Link to full Text with Trip Pro

103. Seroconversion and immunogenicity evaluation of seasonal influenza vaccine in mice model

Seroconversion and immunogenicity evaluation of seasonal influenza vaccine in mice model 28466037 2018 11 13 2347-3584 27 3 2016 Sep Virusdisease Virusdisease Seroconversion and immunogenicity evaluation of seasonal influenza vaccine in mice model. 260-265 10.1007/s13337-016-0336-6 Influenza virus is epidemiologically very important due to the antigenic variations occurring in it. In present study isolation and identification of influenza virus was attempted from Kasauli and adjoining areas. 71 (...) clinical samples i.e. throat washings were processed and inoculated into the eggs for virus isolation. The isolated strains of H3N2, H1N1 and Influenza B were identified, purified and passaged in eggs. The harvested virus was inactivated by 0.03 % formalin and three formulations of crude, inactivated, whole virus monovalent vaccine for H3N2, H1N1 and influenza B as well as a trivalent vaccine was prepared. The immunogenicity study of the vaccine was performed in the mouse model by using varying

Virusdisease2016 Full Text: Link to full Text with Trip Pro

104. Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children: A Cluster Randomized Blinded Trial.

Live Attenuated Versus Inactivated Influenza Vaccine in Hutterite Children: A Cluster Randomized Blinded Trial. Background: Whether vaccinating children with intranasal live attenuated influenza vaccine (LAIV) is more effective than inactivated influenza vaccine (IIV) in providing both direct protection in vaccinated persons and herd protection in unvaccinated persons is uncertain. Hutterite colonies, where members live in close-knit, small rural communities in which influenza virus infection (...) regularly occurs, offer an opportunity to address this question. Objective: To determine whether vaccinating children and adolescents with LAIV provides better community protection than IIV. Design: A cluster randomized blinded trial conducted between October 2012 and May 2015 over 3 influenza seasons. (ClinicalTrials.gov: NCT01653015 ). Setting: 52 Hutterite colonies in Alberta and Saskatchewan, Canada. Participants: 1186 Canadian children and adolescents aged 36 months to 15 years who received

Annals of Internal Medicine2016

105. Differential proteomic analysis of respiratory samples from patients suffering from influenza

Differential proteomic analysis of respiratory samples from patients suffering from influenza 28466033 2018 11 13 2347-3584 27 3 2016 Sep Virusdisease Virusdisease Differential proteomic analysis of respiratory samples from patients suffering from influenza. 226-233 10.1007/s13337-016-0332-x The exact molecular pathways involved in the pathogenesis of influenza are yet unclear. In the present study we investigated the upper respiratory proteome in influenza patients. 200 nasal and throat swab (...) samples were collected from patients suffering from acute respiratory illness. These samples were confirmed for influenza pandemic A/H1N1/2009 and influenza type B using qRT-PCR. 10 similar swabs were collected from healthy individuals and were used as controls. Proteins were extracted from the cell pellets and were subjected to 2-D gel electrophoresis. The differentially expressed proteins were identified using MALDI-TOF. Identified proteins were classified into different functional groups based

Virusdisease2016 Full Text: Link to full Text with Trip Pro

106. Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia—a new therapeutic strategy?

Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia—a new therapeutic strategy? 27480877 2016 08 02 2018 11 13 2194-7791 3 1 2016 Dec Molecular and cellular pediatrics Mol Cell Pediatr Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia-a new therapeutic strategy? 29 10.1186/s40348-016-0055-5 Influenza viruses (IVs) circulate seasonally and are a common cause of respiratory infections (...) . 2002 Jul 15;166(2):138-43 12119223 Curr Opin Virol. 2012 Jun;2(3):233-41 22608464 Am J Physiol Lung Cell Mol Physiol. 2015 Jun 1;308(11):L1178-88 26033355 J Immunol. 2004 Nov 15;173(10):6384-92 15528378 AEC ARDS GM-CSF Influenza Pneumonia Therapy 2016 05 02 2016 07 15 2016 8 3 6 0 2016 8 3 6 0 2016 8 3 6 1 ppublish 27480877 10.1186/s40348-016-0055-5 10.1186/s40348-016-0055-5 PMC4969252

Molecular and cellular pediatrics2016 Full Text: Link to full Text with Trip Pro

107. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data

Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from

NIHR HTA programme2016

108. Pandemic influenza vaccine H5N1 MedImmune

Pandemic influenza vaccine H5N1 MedImmune 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 01 April 2016 EMA/CHMP/323530/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Pandemic influenza vaccine H5N1 MedImmune Common name: pandemic influenza vaccine (H5N1) (live attenuated, nasal) Procedure No. EMEA (...) aminotransferase ANC absolute neutrophil count AOM acute otitis media ASC antibody secreting cell AST aspartate aminotransferase att attenuated ca cold-adapted CAIV-T influenza virus vaccine, trivalent, types A and B, live cold-adapted CDC Centers for Disease Control and Prevention CI confidence interval CMI cell-mediated immunity CSR clinical study report CRADA cooperative research and development agreement CTL cytotoxic T-lymphocyte DOD Department of Defense ELISA enzyme-linked immunosorbent assay ELISPOT enzyme

European Medicines Agency - EPARs2016

109. Seasonal Influenza Infections and Cardiovascular Disease Mortality

Seasonal Influenza Infections and Cardiovascular Disease Mortality 27438105 2018 06 26 2018 11 13 2380-6591 1 3 2016 06 01 JAMA cardiology JAMA Cardiol Seasonal Influenza Infections and Cardiovascular Disease Mortality. 274-81 10.1001/jamacardio.2016.0433 Cardiovascular deaths and influenza epidemics peak during winter in temperate regions. To quantify the temporal association between population increases in seasonal influenza infections and mortality due to cardiovascular causes and to test (...) if influenza incidence indicators are predictive of cardiovascular mortality during the influenza season. Time-series analysis of vital statistics records and emergency department visits in New York City, among cardiovascular deaths that occurred during influenza seasons between January 1, 2006, and December 31, 2012. The 2009 novel influenza A(H1N1) pandemic period was excluded from temporal analyses. Emergency department visits for influenza-like illness, grouped by age (≥0 years and ≥65 years

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

110. Antiviral activity of the oseltamivir and Melissa officinalis L. essential oil against avian influenza A virus (H9N2)

Antiviral activity of the oseltamivir and Melissa officinalis L. essential oil against avian influenza A virus (H9N2) 27366768 2016 07 01 2018 11 13 2347-3584 27 2 2016 Jun Virusdisease Virusdisease Antiviral activity of the oseltamivir and Melissa officinalis L. essential oil against avian influenza A virus (H9N2). 170-8 10.1007/s13337-016-0321-0 Lemon balm derivatives are going to acquire a novelty as natural and potent remedy for treatment of viral infections since the influenza viruses (...) are developing resistance to the current antivirals widely. Oseltamivir, Melissa officinalis essential oil (MOEO) and their synergistic efficacy against avian influenza virus (AIV) subtype H9N2 were evaluated in vitro in MDCK cells at different time exposure by using TCID50, HA, Real Time PCR and HI assay. The results showed that MOEO could inhibit replication of AVI through the different virus replication phase (P ≤ 0.05). Also the highest antiviral activity of MOEO was seen when AIV incubated with MOEO

Virusdisease2016 Full Text: Link to full Text with Trip Pro

111. The emergence and consistency of influenza strains causing influenza like illness in Himachal Pradesh, India

The emergence and consistency of influenza strains causing influenza like illness in Himachal Pradesh, India 27366763 2016 07 01 2018 11 13 2347-3584 27 2 2016 Jun Virusdisease Virusdisease The emergence and consistency of influenza strains causing influenza like illness in Himachal Pradesh, India. 130-5 10.1007/s13337-016-0312-1 The present study offers the status of ongoing surveillance influenza at National Influenza Surveillance Centre (NISC), Central Research Institute (CRI), Kasauli (...) for the emergence and consistency of influenza strains for current as well as over a period of three decades in Solan, Himachal Pradesh. From 1980 to 2015, various clinical centers of Himachal reported counts of influenza-like illness (fever including cough or sore throat). During these years, the respiratory specimens of 6581 patients showing influenza-like illness were collected. The incidence of visits had been calculated for influenza-like illness using the size of the patient population, and the incidence

Virusdisease2016 Full Text: Link to full Text with Trip Pro

112. Oseltamivir (Tamiflu) - for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza

Oseltamivir (Tamiflu) - for the treatment of infants less than 1 year of age including full term neonates who present with symptoms typical of influenza Final Appraisal Recommendation Advice No: 0316 – February 2016 Oseltamivir (Tamiflu ® ) 30 mg, 45 mg and 75 mg capsules, and 6 mg/ml powder for oral suspension Limited submission by Roche Products Ltd Additional note(s): • Please refer to the Summary of Product Characteristics for the full licensed indication. In reaching the above (...) including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.

All Wales Medicines Strategy Group2016

113. Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study.

Safety of Seasonal Influenza Vaccination in Hospitalized Surgical Patients: A Cohort Study. BACKGROUND: Despite recommendations to vaccinate surgical inpatients against influenza, vaccination rates remain low in this population, due in part to concerns about potential negative effects on postsurgical care. OBJECTIVE: To evaluate whether influenza vaccination in the perioperative period increases health care utilization and evaluations for postsurgical infection after discharge. DESIGN (...) : Retrospective cohort study. SETTING: Members of Kaiser Permanente Southern California. PARTICIPANTS: Patients aged 6 months or older who had inpatient surgery with admission and discharge between 1 September and 31 March from 2010 to 2013. MEASUREMENTS: All influenza vaccinations administered between 1 August and 30 April in the 2010-2011, 2011-2012, and 2012-2013 influenza seasons. Outcomes included rates of outpatient visits, readmission, emergency department (ED) visits, fever (temperature ≥38.0 °C

Annals of Internal Medicine2016

114. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord

Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord WHO IRIS: Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans (...) l’hémisphère Nord Browse Related links Files in This Item: File Description Size Format 2.03 MB Adobe PDF Title: Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season = Composition recommandée pour les vaccins antigrippaux devant être utilisés pendant la saison grippale 2016-2017 dans l’hémisphère Nord Authors: Issue Date: 11-Mar-2016 Publisher: World Health Organization = Organisation mondiale de la Sant Journal: Weekly Epidemiological Record

WHO2016

115. Influenza: from zoonosis to pandemic

Influenza: from zoonosis to pandemic 27730163 2018 11 13 2312-0541 2 1 2016 Jan ERJ open research ERJ Open Res Influenza: from zoonosis to pandemic. 00013-2016 Global surveillance and advances in vaccine technology are essential to answer the threat of influenza pandemics http://ow.ly/Yt3e4. Reperant Leslie A LA Artemis One Health Research Foundation, Utrecht, The Netherlands. Moesker Fleur M FM Dept of Viroscience, Erasmus Medical Centre, Rotterdam, The Netherlands. Osterhaus Albert D M E AD

ERJ open research2016 Full Text: Link to full Text with Trip Pro

116. Oseltamivir (Tamiflu) - Treatment of influenza in children aged <1 year including full term neonates

Oseltamivir (Tamiflu) - Treatment of influenza in children aged <1 year including full term neonates Published 07 March 2016 Product Update: oseltamivir 30mg, 45mg, 75mg capsules and 6mg/mL powder for oral suspension (Tamiflu ® ) SMC No. (1127/16) Roche Products Limited 05 February 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission oseltamivir (Tamiflu ® ) is accepted for use within NHS Scotland. Indication under review: Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms. Oseltamivir is listed in the British National Formulary for Children

Scottish Medicines Consortium2016

117. Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis.

Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. BACKGROUND: Cystic fibrosis is the most common, life-threatening, recessively inherited disease of Caucasian populations. It is a multisystem disorder caused by a mutation in the gene encoding the cystic fibrosis transmembrane conductance regulator protein which is important in producing sweat, digestive juices and mucus.The impaired or absent function of this protein results in the production (...) of viscous mucus within the lungs and an environment that is susceptible to chronic airway obstruction and pulmonary colonization by a range of pathogenic bacteria. Morbidity and mortality of cystic fibrosis is related to chronic pulmonary sepsis and its complications by these bacteria.Influenza can worsen the course of the disease in cystic fibrosis by increasing the risk of pneumonia and secondary respiratory complications. Antiviral agents form an important part of influenza management and include

Cochrane2016

118. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease.

Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. BACKGROUND: People affected with sickle cell disease are at high risk of infection from Haemophilus influenzae type b. Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a high mortality rate in children under five years of age. In African countries, where coverage of this vaccination is still extremely low, Haemophilus influenzae type b (...) remains one of the most common cause of bacteraemias in children with sickle cell disease. The increased uptake of this conjugate vaccination may substantially improve the survival of children with sickle cell disease. OBJECTIVES: The primary objective was to determine whether Haemophilus influenzae type b conjugate vaccines reduce mortality and morbidity in children and adults with sickle cell disease.The secondary objectives were to assess the following in children and adults with sickle

Cochrane2016

119. Probable Hospital Cluster of H7N9 Influenza Infection.

Probable Hospital Cluster of H7N9 Influenza Infection. Probable Hospital Cluster of H7N9 Influenza Infection. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26863372 Format MeSH and Other Data E-mail Subject (...) Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Feb 11;374(6):596-8. doi: 10.1056/NEJMc1505359. Probable Hospital Cluster of H7N9 Influenza Infection. 1 , 2 , 1 , 1 , 1 , 1 , 2 , 2 , 3 , 4 , 4 , 5 , 5 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 2 , 4 , 3 , 3 , 6 , 5 , 7 ; . 1 Shantou University Medical College, Shantou, China. 2 Second Affiliated Hospital, Shantou, China. 3

NEJM2016

120. Characterization of evolutionary changes in hemagglutinin of influenza H1N1 virus: a computational analysis

Characterization of evolutionary changes in hemagglutinin of influenza H1N1 virus: a computational analysis 26925442 2016 02 29 2018 11 13 2347-3584 27 1 2016 Mar Virusdisease Virusdisease Characterization of evolutionary changes in hemagglutinin of influenza H1N1 virus: a computational analysis. 34-40 10.1007/s13337-015-0294-4 Influenza virus continues to evolve due to changes in the genome and the new strain of virus is more pathogenic then the previous strain. These changes may also help

Virusdisease2016 Full Text: Link to full Text with Trip Pro